Recent Trend for EGFR-Based and ALK-Based Targets: A Patent Analysis.
1Central International Intellectual Property (Baotou) Co., Ltd., Baotou, Inner Mongolia 014030, China.
Large pharmaceutical companies dominate intellectual property for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) targeted cancer therapies. Research shows EGFR remains an attractive target, with small molecule inhibitors leading patent filings.
Area of Science:
- Oncology
- Pharmaceutical Research
- Intellectual Property Analysis
Background:
- Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are crucial in cancer development.
- Targeted therapies offer advantages over traditional chemotherapy for cancer treatment.
- EGFR and ALK are significant targets for novel drug development.
Purpose of the Study:
- To analyze recent trends in research and development (R&D) for EGFR and ALK targets.
- To understand the intellectual property landscape surrounding EGFR and ALK targets.
Main Methods:
- Comprehensive US patent analysis of EGFR-based and ALK-based targets.
- Data collection spanned from September 2001 to September 2020.
Main Results:
- Key technologies for EGFR/ALK targets are primarily developed by major global pharmaceutical firms and US entities.
- Small molecule inhibitors represent a significant portion of patents for EGFR-based targets.
- Recent FDA-approved small molecule targeted drugs were identified.
Conclusions:
- Global pharmaceutical giants and US academic/corporate institutions lead in targeted drug R&D.
- EGFR continues to be a highly pursued target for cancer research and drug development.
- Leading pharmaceutical companies favor independent innovation over collaborations for key technology development.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
